Wedbush Maintains Outperform on Oruka Therapeutics, Raises Price Target to $85

Benzinga Newsdesk www.benzinga.com Positive 83.1%

Neg 0% Neu 0% Pos 83.1%

Wedbush analyst Martin Fan maintains Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and raises the price target from $45 to $85.